Volume is not important as compared to quality in the manufacturing process for FDA, particularly with a novel, expensive therapy that has an unmet need. They will never constrain and limit innovation as long as the clinical trial data (safety, efficacy) is backed up with quality application.
Kite could only produce doses for 100 patients in the first year of their commercial journey post FDA approval.
Don't fall in the trap set by the social media army!
Market Data 
Markets 
